{"id":"NCT03006276","sponsor":"BioDelivery Sciences International","briefTitle":"Efficacy, Tolerability, and Safety Study of DFN-15","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2017-11","completion":"2019-05","firstPosted":"2016-12-30","resultsPosted":"2023-01-10","lastUpdate":"2023-01-10"},"enrollment":622,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Headache"],"interventions":[{"type":"DRUG","name":"DFN-15 Active","otherNames":["Celecoxib Oral Solution"]},{"type":"OTHER","name":"DFN-15 Placebo","otherNames":[]}],"arms":[{"label":"DFN-15 Active","type":"EXPERIMENTAL"},{"label":"DFN-15 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.","primaryOutcome":{"measure":"Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)","timeFrame":"2 hours post dose","effectByArm":[{"arm":"Placebo LOCF","deltaMin":21.7,"sd":null},{"arm":"DFN-15 LOCF","deltaMin":35.6,"sd":null},{"arm":"Placebo OC","deltaMin":22.1,"sd":null},{"arm":"DFN-15 OC","deltaMin":35.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://pubmed.ncbi.nlm.nih.gov/31647577/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":282},"commonTop":["Dysgeusia","Nausea"]}}